Novo's Victoza beats Januvia in study; New Actavis chief promises growth by acquisition;

  @FiercePharma: J&J recall plant to stay closed through year's end. Article | Follow @FiercePharma

> Novo Nordisk said extension data from a study showed its new diabetes drug Victoza provided better blood sugar control and weight reduction than Merck's blockbuster Januvia. Report

> Icelandic generic drug maker Actavis aims to become the world's third-largest manufacturer of copycat medicines via acquisitions, CEO Claudio Albrecht told Dow Jones in an interview. Report

> Britain's health cost watchdog has changed tack and recommended that rheumatoid arthritis patients should have more options if they do not respond adequately to treatment with a so-called TNF inhibitor drug. Report

> Sun Pharmaceutical Industries will stop selling a generic version of Sanofi-Aventis' cancer drug Eloxatin in the U.S. after June 30 following a court order, the Indian drugmaker said. Report

> FDA said it does not expect any shortage of children's pain and allergy medications despite Johnson & Johnson's inability to resume production until at least next year. Report

> Pharmaceutical sales in France grew 2.7 percent to 26.9 billion euros last year, but retail sales of non-reimbursable drugs advanced 3.6 percent, according to new industry figures. Report

Biotech News

@FierceBiotech: Analysts fret over Pfizer's litany of pipeline snafus. Article | Follow @FierceBiotech

@JohnCFierce: Now the 3 obesity drug developers, Vivus, Orexigen and Arena, have panels lined up, when do partners step up with the big bucks? Why so late? | @JohnCFierce

> Eisai blueprints new R&D center in India. Report

> As R&D budgets slide, declining output mires pharma pipeline. Item

> Doc sentenced to prison for faking research data. Story

> Analysts turn bearish on Roche's taspoglutide prospects. Article

> New diabetes data highlights promising drug class. Story

> AZ will open compound library to malaria researchers. News

Biotech IT News

> Symyx software helps bridge biologic/chemical gap. Item

> Cloudera, Quest Software to partner. News

> Investigators turn to new 3D imaging tech in bone study. Report

> Seattle start-up attracts early adopters of cancer drug tech. Story

> IBM touts cloud computing's ability to cut trial costs. Item

And Finally... What would happen in a world that accepts no risks in its pharmaceuticals? We would have very empty medicine cabinets. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.